Management of bipolar disorder in the intercontinental region: an international, multicenter, non-interventional, cross-sectional study in real-life conditions.

Journal: Scientific reports

Volume: 6

Issue: 

Year of Publication: 2018

Affiliated Institutions:  CHU Clermont-Ferrand, EA, University of Auvergne, Clermont-Ferrand, France. Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain. Institute of Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt. National Institute of Neurosciences and Hospital, Sher-e-Bangla Nagar, Dhaka, Bangladesh. Roozbeh Hospital, South Kargar Street, Tehran, Iran. Psychiatric Department, Razi Hospital, Manouba, Tunisia. Kyiv City Clinical Psycho-neurological Hospital, Kiev, Ukraine. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Sha'ar Menashe Mental Health Center (MHC), Technion Institute of Technology, Haifa, Israel. Biostatistician, Experis IT, Nanterre, France. Sanofi, Avenue Raspail, Gentilly, France.

Abstract summary 

Most of the existing data on real-life management of bipolar disorder are from studies conducted in western countries (mostly United States and Europe). This multinational, observational cohort study aimed to describe the management and clinical outcomes of bipolar patients in real-life conditions across various intercontinental countries (Bangladesh, Egypt, Iran, Israel, Tunisia, and Ukraine). Data on socio-demographic and disease characteristics, current symptomatology, and pharmacological treatment were collected. Comparisons between groups were performed using standard statistical tests. Overall, 1180 patients were included. The median time from initial diagnosis was 80 months. Major depressive disorder was the most common initial diagnosis. Mood stabilizers and antipsychotics were the most common drugs being prescribed at the time of the study. Antidepressants (mainly selective serotonin uptake inhibitors [SSRIs]) were administered to 36.1% of patients. Patients with bipolar I disorder received higher number of antipsychotics and anxiolytics than those with bipolar II disorder (p < 0.001). Presence of depressive symptoms was associated with an increase in antidepressant use (p < 0.001). Bipolar disorder real-life management practice, irrespective of region, shows a delay in diagnosis and an overuse of antidepressants. Clinical decision-making appears to be based on a multidimensional approach related to current symptomatology and type of bipolar disorder.

Authors & Co-authors:  Samalin Ludovic L Vieta Eduard E Okasha Tarek Ahmed TA Uddin Mm Jalal MJ Ahmadi Abhari Seyed Ali SA Nacef Fethi F Mishyiev Vyacheslav V Aizenberg Dovi D Ratner Yaël Y Melas-Melt Lydie L Sedeki Idir I Llorca Pierre Michel PM

Study Outcome 

Source Link: Visit source

Statistics
Citations :  World Health Organization. The Global Burden of Disease: 2004 Update. (2008) Available at:http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/ (Accessed: 28th September 2015).
Authors :  12
Identifiers
Doi : 25920
SSN : 2045-2322
Study Population
Male,Female
Mesh Terms
Adult
Other Terms
Study Design
Cohort Study,,Cross Sectional Study
Study Approach
Country of Study
Tunisia
Publication Country
England